The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis

Ozdogan H., UĞURLU S., UYGUNOĞLU U., TÜTÜNCÜ M., Gül A., Akman G., ...More

MULTIPLE SCLEROSIS AND RELATED DISORDERS, vol.45, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2020
  • Doi Number: 10.1016/j.msard.2020.102332
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Keywords: Familial mediterranean fever (FMF), Multiple sclerosis (MS), Colchicine resistant, Anti-interleukin-1 treatment, Anakinra, Canakinumab, DISEASE-MODIFYING TREATMENTS, NERVOUS-SYSTEM INVOLVEMENT, COLCHICINE-RESISTANT
  • Istanbul University Affiliated: Yes


It has been reported that multiple sclerosis (MS) is more common among patients with familial Mediterranean fever (FMF) than expected in normal population. Also, an association between MEFV gene variants and disease severity in MS has been described. Excessive production of interleukin-1 (IL-1) beta is responsible for FMF pathogenesis, and anti-IL-1 treatment is an effective approach in colchicine-resistant FMF patients. Here, we describe three patients with FMF and coexisting MS who have been treated with anti-IL-1 agents. Our observations suggest that blocking IL-1 is a safe and an effective alternative for colchicine resistant FMF and probably also for associated MS.